BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 5, 2015 /CNW/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Stifel 2015 Healthcare Conference on Wednesday, November 18, 2015 at 2:15 p.m. EST at the New York Palace Hotel in New York City. The presentation will include an overview of the Phase 3 custirsen program, as well as the company's Phase 2 apatorsen development plans and timelines.
A live audio webcast can be accessed via http://www.veracast.com/webcasts/stifel/healthcare2015/05209772189.cfm or through the Investor Relations page of the OncoGenex website at www.oncogenex.com. The webcast replay will be archived for 60 days.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com and at the company's Twitter account: https://twitter.com/OncoGenex_IR.
SOURCE OncoGenex Pharmaceuticals, Inc.
For further information: Investor Relations Contact: Jim DeNike, firstname.lastname@example.org, +1-425-686-1514, http://www.oncogenex.com/